Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34407545/

E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus six cycles of rituximab (IR) to six cycles of fludarabine, cyclophosphamide and rituximab (FCR) in untreated younger patients with...

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34572809/

1 Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Modena, 41124 Modena, Italy. 2 Section of Hematology, Department of Medical and Surgical Sciences, University of Modena...

Roadmap to cure multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34597912/

Despite significant advances in the treatment of multiple myeloma which had led to unprecedented rates of response and survival, patients still relapse, and cure remains elusive. We propose in this...

Pediatric Mixed-Phenotype Acute Leukemia: What's New?

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469808/

Pediatric mixed-phenotype leukemia is a rare form of blood cancer in children. In this review, we cover both the evolution of treatment over the past several years and outline new...

The road to chemotherapy-free treatment in chronic lymphocytic leukaemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34474439/

Currently available treatment approaches for CLL offer the opportunity to individualize therapy for every single patient with CLL. Inhibitors of B-cell receptor (BCR) signalling pathways and antiapoptotic proteins are nowadays...